Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab

a?? Collaboration to explore multiple solid tumor cancer indicationsAa??
a?? Initial development focused on multi-cohort trials in the U.S., Europe, China and AustraliaAa??LONDON and CAMBRIDGE, Mass. and BEIJING, China, May 26, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (a??Chi-Meda??) (Nasdaq/AIM: HCM) and BeiGene, Ltd. (a??BeiGenea??) (Nasdaq: BGNE; HKEX: 06160) today announced that they have entered into a clinical collaboration agreement to evaluate the safety, tolerability and efficacy of combining two of Chi-Meda??s drug candidates, surufatinib and fruquintinib, with BeiGenea??s anti-PD-1 antibody tislelizumab, for the treatment of various solid tumor cancers, in the U.S., Europe, China and Australia.AUnder the terms of the agreement, Chi-Med and BeiGene each plan to explore development of the combination of surufatinib with tislelizumab or fruquintinib with tislelizumab in different indications and regions.AThe companies have agreed to provide mutual drug supply and other support.a??We are very pleased to enter into this clinical collaboration with BeiGene, a company with which we share a vision to discover, develop and commercialize innovative targeted therapies and immunotherapies worldwide,a?? said Dr. Marek Kania, Senior Vice President and Chief Medical Officer, Hutchison MediPharma International.1
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«     2020    »